Aktuelle Diagnostik und Therapiekonzepte für das Pankreaskarzinom

Das duktale Adenokarzinom des Pankreas zählt immer noch zu den Tumoren mit der ungünstigsten Prognose. Präventionsmöglichkeiten und spezifische Frühsymptome fehlen – häufig wird die Diagnose erst im fortgeschrittenen Stadium gestellt. Daher ist für die meisten Patienten eine Systemtherapie indiziert. In den letzten Jahren führten neu zugelassene Medikamente, neue Kombinationen und sequenzielle Therapiekonzepte dabei zu deutlichen Fortschritten.

Schlüsselwörter

Pankreaskarzinom - Kriterien der Tumorausdehnung - Therapiestrategien

• Literatur

• 1 Robert-Koch-Institut, Zentrum für Krebsregisterdaten. Krebs in Deutschland für 2013/2014. Berlin: Robert Koch-Institut; 2017: 48-51
• 2 Petersen GM. Familial pancreatic adenocarcinoma. Hematol Oncol Clin North Am 2015; 29: 641-653
• 3 Harder J, Ihorst G, Heinemann V. et al. Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. Br J Cancer 2012; 106: 1033-1038
• 4 Cancer Genome Atlas Research Network. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell 2017; 32: 185-203
• 5 Seufferlein T, Porzner M, Becker T. et al. S3-Leitlinie zum exokrinen Pankreaskarzinom. Z Gastroenterol 2013; 51: 1395-1440
• 6 Duffy MJ, Sturgeon C, Lamerz R. et al. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol 2010; 21: 441-447
• 7 Al-Hawary MM, Francis IR, Chari ST. et al. Pancreatic Ductal Adenocarcinoma Radiology Reporting template: Consensus Statement of the Society of Abdominal Radiology and the American Pancreatic Association. Radiology 2014; 270: 248-260
• 8 Lutz MP, Zalcberg JR, Ducreux M. et al. 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. Eur J Cancer 2017; 79: 41-49
• 9 van der Gaag NA, Rauws EA, Casper HJ. et al. Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med 2010; 362: 129-137
• 10 Hashmi A, Kozick F, Fluck M. et al. Neoadjuvant versus adjuvant chemotherapy for resectable pancreatic adenocarcinoma: A National Cancer Database Analysis. Am Surg 2018; 84: 1439-1445
• 11 Hackert T. Surgery for pancreatic cancer after neoadjuvant treatment. Ann Gastroenterol Surg 2018; 2: 413-418
• 12 Barenboim A, Lahat G, Geva R. et al. Neoadjuvant FOLFIRINOX for locally adcanced and borderline resectable pancreatic cancer: An intention to treat analysis. Eur J Surg Oncol 2018; 44: 1619-1623
• 13 Oettle H, Post S, Neuhaus P. et al. Adjuvant chemotherapy with gemcitabine vs. observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297: 267-277
• 14 Neoptolemos JP, Dunn JA, Stocken DD. et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a radomised controlled trial. Lancet 2001; 358: 1576-1585
• 15 Neoptolemos JP, Moore MJ, Cox TF. et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs. observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA 2012; 308: 147-156
• 16 Sinn M, Bahra M, Liersch T. et al. CONKO-005: Adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: a multicenter randomized phase III trial. J Clin Oncol 2017; 35: 3330-3337
• 17 Neoptolemos JP, Palmer DH, Ghaneh P. et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomized, phase 3 trial. Lancet 2017; 389: 1011-1024
• 18 Conroy T, Hammel P, Hebbar M. et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 2018; 379: 2395-2406
• 19 Valle JW, Palmer D, Jackson R. et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol 2014; 32: 504-512
• 20 Conroy T, Desseigne F, Ychou M. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825
• 21 von Hoff DD, Ervin T, Arena FP. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691-1703
• 22 Macarulla T, Pazo-Cid R, Guillén-Ponce C. et al. Phase I/II trial to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with pancreatic cancer and an ECOG performance status of 2. J Clin Oncol 2019; 37: 230-238
• 23 Goldstein D, El-Maraghi RH, Hammel P. et al. Nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst 2015; 107: 413
• 24 Tong H, Fan Z, Lui B. et al. The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis. Sci Rep 2018; 8: 8666
• 25 Golan T, Hammel P, Reni M. et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 2019; 381: 317-327
• 26 Terazawa T, Goto M, Takahiro M. et al. The efficacy of prophylactic GCSF for FOLFIRINOX. J Clin Oncol 2015; 33 (Suppl. 03) 274
• 27 Boeck S, Heinemann V. Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer. J Clin Oncol 2008; 26: 1178-1179
• 28 Oettle H, Riess H, Stieler JM. et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol 2014; 32: 2423-2429
• 29 Gill S, Ko YJ, Cripps C. et al. PANCREOX: A randomized phase III study of fluorouracil/leukovorin with or without oxaliplatin for second-line advanced pancratic cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol 2016; 34: 3914-3920
• 30 Wang-Gillam A, Li CP, Bodoky G. et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomized, open-label, phase 3 trial. Lancet 2016; 387: 545-557
• 31 Portal A, Pernot S, Tougeron D. et al. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicenter cohort. Br J Cancer 2015; 113: 989-995
• 32 Kowalewski A, Szylberg L, Saganek M. et al. Emerging strategies in BRCA-positive pancreatic cancer. J Cancer Res Clin Oncol 2018; 144: 1503-1507
• 33 Heining C, Horak P, Uhrig S. et al. NRG1 fusions in KRAS wild-type pancreatic cancer. Cancer Discov 2018; 8: 1087-1095
• 34 Zi H, Shia J, Stadler ZK. et al. Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations. Clin Cancer Res 2018; 24: 1326-1336